TAT-CBD3 peptide

TAT-CBD3 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

H-YGRKKRRQRRRARSRLAELRGVPRGL-OH

H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Ala-Arg-Ser-Arg-Leu-Ala-Glu-Leu-Arg-Gly-Val-Pro-Arg-Gly-Leu-OH

26

95.19%

C₁₃₄H₂₄₃N₅₉O₃₂

3192.73

Synthetic

Powder

TAT-CBD3 is the 15-amino acid peptide derived from the axonal collapsin response mediator protein 2 (CRMP-2) conjugated to the cell penetrating motif of the HIV transduction domain protein TAT, which is a modulator of N-type voltage-gated calcium channels (CaV2.2). TAT-CBD3 functions as a CRMP2 - CaV2.2 interaction inhibitor and reduces CaV2.2 mediated currents, and also reduces T-type currents, which results in reduced nociceptor excitability, diminished neuropeptide release from sensory neurons and lower excitatory synaptic transmission. TAT-CBD3 can also reduce hypersensitive behaviour in chemical-induced inflammatory and neuropathic animal pain models.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Brittain et al (2011) Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca2+ channel complex. Nature Med. 17(7) 822 PMID: 21642979
• Fischer et al (2014) Sustained relief of neuropathic pain by AAV-targeted expression of CBD3 peptide in rat dorsal root ganglion. Gene Ther. 21(1) 44 PMID: 24152582

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.